Focused on precision oncology, the company develops targeted therapies for cancers driven by mutations in the RAS/MAPK signaling pathway. Its pipeline consists primarily of small‑molecule inhibitors and combination strategies aimed at difficult‑to‑treat solid tumors, with several candidates in clini...
No congressional trades have been disclosed for Erasca, Inc. (ERAS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.